A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients

• Written informed consent must be obtained before any assessment is performed.

• Adults greater than or equal to 18 years of age upon entry into screening.

• Documented history of migraine (with or without aura) greater than or equal to 12 months prior to screening according to the International Classification of Headache Disorders-3rd Edition (ICHD-3).

• Greater than or equal to 4 and less than 15 days per month of migraine symptoms (based on ICHD-3 criteria) on average across 3 months prior to screening based on retrospective reporting.

• Less than 15 days per month of headache symptoms (i.e., migraine and non-migraine).

• Subjects in need for switching by documented failure of 1 or 2 prophylactic treatments in the last 6 months due to either lack of efficacy or poor tolerability. For subjects with 1 prior treatment failure, the failure should have occurred in the last 6 months. For subjects with 2 prior treatment failures, the second treatment failure should have occurred in the last 6 months.

• During baseline: Confirmed migraine frequency of 4 to 14 migraine days and less than 15 days of headache symptoms.

• During baseline: greater than or equal to 80% compliance with the headache diary.